Purpose: This study evaluated the safety and efficacy of photoselective vaporization of prostate using the 120 W High Performance System for management of symptomatic benign prostatic hyperplasia (BPH). Methods: We prospectively obtained data from 229 patients between January 2009 and December 2012. We evaluated the serum prostate specific antigen level, International Prostate Symptom Score (IPSS), prostate volume; maximum urine flow rate (Qmax); and postvoid residual urine volume (PVR) in the patients at presentation and on follow-up at 1, 6, 12, and 24 months. The mean duration of the surgery, energy used, hospital stay, and intra- and postoperative complications were assessed. Results: The mean age of the patients was 71.2 ± 9.6 years, and the mean preoperative size of the prostate was 59.41 ± 28.1 mL. The mean duration of the surgery was 47.35 ± 16.14 min, and the mean energy use was 184.39 ± 101.3 kJ. The mean time to removal of the urinary catheter was 21.45 ± 11.06 h, while the mean duration of hospital stay was 24.82 ± 11.5 h. The IPSS declined and mean Qmax increased by over twofold within the first month. The PVR also declined significantly in all groups up to 6 months after the surgery and increased slightly thereafter. Urinary urgency and incontinence occurred in two patients, while four patients developed urinary strictures. Between 12 and 24 months after the surgery, four patients underwent repeat surgery. Conclusions: Our findings show that photoselective vaporization is safe and effective for the management of BPH and resulted in few complications. It yielded improvements in all parameters that were sustained even up to 2 years after the surgery.
Get full access to this article
View all access options for this article.
References
1.
KramerG, MittereggerD, MarbergerM. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol, 2007; 51:1202–1216.
2.
SrivastavaA, GuptaVB. Various treatment options for benign prostatic hyperplasia: a current update. J Midlife Health, 2012; 3:10–19.
3.
WeiJT, CalhounE, JacobsenSJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol, 2005; 173:1256–1261.
4.
MayerEK, KroezeSG, et al.Examining the ‘gold standard’: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int, 2012; 110:1595–1601.
5.
HöfnerK, TunnU-W, ReichO, RübbenH. Surgery for benign prostatic hyperplasia. Dtsch Arztebl, 2007; 104:2424–2429.
6.
ChenLJ, MaiHX, ZhaoL, et al.Experience of treating high risk prostate hyperplasia patients with a HPS120 laser. BMC Urol, 2013; 13:64.
7.
WooH, ReichO, et al.Outcome of GreenLight HPS 120-W laser therapy in specific patient populations: those in retention, on anticoagulants, and with large prostates (≥80 mL). Eur Urol Suppl, 2008; 7:378–383.
8.
KangHW, JebensD, MalekRS, MitchellG, KoullickE. Laser vaporization of bovine prostate: a quantitative comparison of potassium-titanyl-phosphate and lithium triborate lasers. J Urol, 2008; 180:2675–2680.
9.
Al-AnsariA, YounesN, SampigeVP, et al.GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol, 2010; 58:349–355.
10.
ChoiYS, BaeWJ, KimSJ, et al.Efficacy and safety of 120-W GreenLight High-Performance System laser photo vaporization of the prostate: 3-year results with specific considerations. Prostate Int, 2013; 1:169–176.
11.
MosliHA, Abdel-MeguidTA, AbdulwahhabMH, Al-SayyadA, FarsiHM, TayibA. Photoselective vaporization of the prostate using GreenLight 120-W lithium triborate laser to treat symptomatic benign prostatic hyperplasia: a single-centre prospective study. Can Urol Assoc J, 2013; 7:E193–E196.
12.
DyachukVD. Estimation of clinical efficacy of modified laser vaporization for benign prostatic hyperplasia. Klin Khir, 2015; 5:73–76.
13.
BaturaD, SahibzadaI, ElkabirJ, et al.Durability and complications of photoselective vaporization of the prostate with the 120 W high performance system GreenLight™ lithium triborate laser. Ann R Coll Surg Engl, 2014; 96:359–363.
14.
TengJ, ZhangD, LiY, et al.Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int, 2013; 111:312–323.
15.
DingH, DuW, LuZP, ZhaiZX, WangHZ, WangZP. Photoselective green-light laser vaporization vs. TURP for BPH: meta-analysis. Asian J Androl, 2012; 14:720–725.
16.
ZangYC, DengXX, YangDR, et al.Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci, 2016; 31:235–240.
17.
CapitánC, BlazquezC, MartinMD, HernandezV, de la PenaE, LlorenteC. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. Eur Urol, 2011; 60:734–739.
18.
LukacsB, LoefflerJ, BruyèreF, et al.Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol, 2012; 61:1165–1173.
19.
Pereira-CorreiaJA, de Moraes SousaKD, SantosJB, et al.GreenLight HPS™ 120-W laser vaporization vs transurethral resection of the prostate (<60 mL): a 2-year randomized double-blind prospective urodynamic investigation. BJU Int, 2012; 110:1184–1189.
20.
TasciAI, TugcuV, SahinS, ZorluogluF. Rapid communication: photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective nonrandomized bicenter trial with 2-year follow-up. J Endourol, 2008; 22:347–353.
